Quantcast

Latest Protease inhibitors Stories

2014-10-01 12:30:59

Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11, 2014. Abstracts will be presented highlighting results from AbbVie's investigational treatment combining three...

2014-09-29 04:21:31

BEERSE, Belgium, September 29, 2014 /PRNewswire/ -- CHMP also issues two label extensions for darunavir Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA(TM) (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1...

2014-09-28 23:02:11

MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Hepatitis C Virus Market is expected to grow during the Forecast Period. Dallas, TX (PRWEB) September 28, 2014 The Hepatitis C Virus Market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main Hepatitis C...

2014-09-17 08:28:44

New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV TORONTO, Sept. 17, 2014 /CNW/ - Janssen Inc. announced today that PREZCOBIX(TM) (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada.(1) It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. "We...

2014-07-28 13:20:36

The Lancet Infected patients and could improve treatment uptake Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. Both studies focused on hepatitis C genotype 1, which is the most common genotype in the USA, Europe, North Asia, Australia, and South America,...

2014-06-19 16:23:51

The Majority of Surveyed Primary Care Physicians Expect to Refer HCV Patients to a Specialist for Care, According to Findings from Decision Resources Group BURLINGTON, Mass., June 19, 2014 /PRNewswire/ -- Decision Resources Group finds that less than one-third of surveyed primary care physicians (PCPs) are familiar with the first-generation hepatitis C virus (HCV) protease inhibitors, Vertex's Incivek and Merck's Victrelis, despite the fact that these direct acting antivirals have been...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-05-07 08:32:30

-- Filing Includes Data from Treatment-Naive Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis -- RARITAN, N.J., May 7, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO(TM) in the United States, in combination with the nucleotide analog NS5B polymerase...

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-04-07 08:30:46

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 7, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related